Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares traded up 5.9% during trading on Tuesday . The company traded as high as $1.65 and last traded at $1.61. 933,500 shares traded hands during trading, an increase of 114% from the average session volume of 436,956 shares. The stock had previously closed at $1.52.

A number of research analysts have recently commented on the stock. Maxim Group set a $3.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 26th. HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research cut shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. ValuEngine raised shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Seaport Global Securities reissued a “buy” rating and set a $5.00 target price on shares of Pluristem Therapeutics in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $4.00.

Pluristem Therapeutics (NASDAQ:PSTI) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). equities analysts expect that Pluristem Therapeutics Inc. will post -0.34 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of PSTI. Heritage Investors Management Corp acquired a new stake in Pluristem Therapeutics in the third quarter valued at $113,000. Psagot Investment House Ltd. raised its holdings in Pluristem Therapeutics by 1,705.2% in the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 122,347 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in Pluristem Therapeutics by 15.0% in the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 34,742 shares in the last quarter. 4.31% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Pluristem Therapeutics (PSTI) Trading 5.9% Higher” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/18/pluristem-therapeutics-psti-trading-5-9-higher.html.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.